This $1,052,276 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and validation of a wearable multimodal sensor system for remote monitoring of patients with chronic obstructive pulmonary disease (COPD). The project, titled "Bilateral Acoustic Sensing and Automated Breathing Segmentation for Remote Monitoring of Patients with COPD: A Longitudinal Study," aims to...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $274,274 to X-Cor Therapeutics Inc., a minority-owned small disadvantaged business in Washington, DC, to develop a novel respiratory dialysis system for treating chronic obstructive pulmonary disease (COPD) patients. The project aims to optimize a prototype that can efficiently remove excess carbon dioxide from the blood of COPD patients, with the goal of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $604,750 to Scientific Horizons Consulting LLC to develop and evaluate a novel inhalation device for the pulmonary delivery of anti-inflammatory agents to manage pain in chronic obstructive pulmonary disease (COPD). The device utilizes a novel "bottom-up" aerosolization technology to generate optimized aerosol particles for deep...
This federal Project Grant award from the National Institute of Nursing Research (CFDA 93.361 Nursing Research) provides $786,734 to the Mayo Clinic in Rochester, MN to conduct a clinical trial testing the uptake, effectiveness, and stakeholder experience of a home-based pulmonary rehabilitation program with health coaching for patients with chronic obstructive pulmonary disease (COPD) in rural communities. The 5-year project aims to address disparities in access to pulmonary rehabilitation,...
This $324,770 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports the development of a novel stand-alone wearable device to monitor environmental exposures and respiratory health for individuals with chronic obstructive pulmonary disease (COPD). The awardee, Canairy LLC, is working to advance a prototype into an intelligent, connected version that can wirelessly transmit data to patients'...
This National Institutes of Health (NIH) R21/R33 grant award in the amount of $734,360 aims to develop and validate an innovative, inexpensive multi-modal digital stethoscope capable of automated lung sound and respiratory rate analysis, with mobile phone interoperability to an electronic health (eHealth) platform for real-time lower respiratory infection (LRI) and antibiotic surveillance in low- and middle-income countries (LMICs). The grant, awarded under the NIH's Child Health and Human...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will evaluate the use of mobile devices to extract vital signs to monitor patients with asthma. The $459,127 award to M5 Enterprise, LLC (doing business as Emedical Sentry) aims to improve the detection and management of asthma attacks through remote patient monitoring. The goal is to enhance telehealth by incorporating video-based vital sign...
This Project Grant award for $626,247 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop a tool that leverages quantitative imaging data from lung cancer screening to identify individuals at risk for undiagnosed chronic obstructive pulmonary disease (COPD). The key objectives are to: 1) Use quantitative imaging analysis of lung cancer screening CT scans to characterize COPD-related pathology and...
This federal Project Grant award of $477,290 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the underlying behavioral mechanisms that contribute to successful outcomes from a home-based pulmonary rehabilitation (PR) program for patients with chronic obstructive pulmonary disease (COPD). The goal is to determine how patterns of physical activity, sedentary behavior, sleep, and cognitive...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $374,378 to Michigan State University to develop a computational modeling framework and prototype for a miniaturized, noninvasive, wireless, luminescence-based carbon dioxide (CO2) sensing wearable device. The key objectives are to: 1) develop computational models of...
BUILDING A DIGITAL RESPIRATORY DISEASE FRAMEWORK FOR COPD MANAGEMENT IN CENTRAL APPALACHIA - PROJECT SUMMARY/ABSTRACT COMPARED TO URBAN RESIDENTS, RURAL COMMUNITIES HAVE HIGHER RATES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH WORSE DISEASE CONTROL, RESULTING IN HIGHER RATES OF MORBIDITY AND MORTALITY. IN GENERAL, RURAL RESIDENTS SUFFER FROM HIGHER POVERTY AND UNINSURED RATES, FURTHER COMPOUNDED BY GEOGRAPHIC ISOLATION AND LIMITED ACCESS TO QUALITY HEALTHCARE. THIS AND OTHER SOCIAL FACTORS HAVE RESULTED IN HIGHER INCIDENCE AND WORSE OUTCOMES OF NEARLY EVERY CHRONIC DISEASE. TELEHEALTH HOLDS PROMISE TO ADDRESS THESE CHALLENGES AND EXPAND ACCESS TO SPECIALIST CARE IN THESE COMMUNITIES, BUT QUALITATIVE TELEHEALTH VISITS OFTEN LACK NECESSARY PATIENT DATA FOR PHYSICIANS TO MAKE INFORMED MANAGEMENT DECISIONS. TELEMEDICINE IS ALSO OFTEN HINDERED BY LIMITED BROADBAND ACCESS IN RURAL AREAS. WEARABLE TECHNOLOGIES FOR REMOTE MONITORING SUFFER SIMILAR LIMITATIONS, AND, DUE TO COST AND BURDENSOME DAILY ENGAGEMENT REQUIREMENTS, LEAD TO POOR ADHERENCE RATES IN AN OLDER, SICKER POPULATION. TO ADDRESS THESE CHALLENGES, MEDENTUM IS DEVELOPING AN AFFORDABLE AND ACCESSIBLE, MULTI-FUNCTIONAL, HOME-USE DEVICE FEATURING A CAMERA, LOW-COST SENSORS (TEMPERATURE, PULSE OXIMETER) AND A DIGITAL STETHOSCOPE. A COMPANION PHONE APPLICATION ALLOWS THE RECORDING OF DEMOGRAPHICS, SOCIOCULTURAL DATA, MEDICAL HISTORY, AND SYMPTOMS, AND GUIDES THE PATIENT TO COLLECT THEIR BIOMETRIC READINGS WITH THE HANDHELD DEVICE. WITHOUT THE NECESSITY OF BROADBAND, THE PATIENT CAN TRANSMIT THEIR INFORMATION SECURELY TO A REMOTE PHYSICIAN/CHRONIC DISEASE SPECIALIST WHO CAN MAKE A DIAGNOSIS AND TREATMENT PLAN. FOR THIS SBIR, MEDENTUM WILL ADAPT ITS DEVICE AND SOFTWARE PLATFORM FOR RESPIRATORY DISEASE, LAYERING IT WITH ARTIFICIAL INTELLIGENCE (AI) ALGORITHMS, TO CREATE A DIGITAL RESPIRATORY DISEASE FRAMEWORK (DRDF) THAT EMPOWERS SELF-MANAGEMENT OF COPD. THE AIMS OF THIS SBIR ARE TO 1) STUDY THE USABILITY AND FEASIBILITY OF THIS COPD RESPIRATORY FRAMEWORK IN A RURAL CENTRAL APPALACHIAN POPULATION OF 75 PATIENTS IN SOUTHWEST VIRGINIA AND 2) BUILD PRELIMINARY AI ALGORITHMS THAT AUTONOMOUSLY PREDICT COPD EXACERBATION RISK BY ANALYZING LOW BURDEN VARIABLES INCLUDING RISK FACTORS (SOCIAL, BEHAVIORAL, ENVIRONMENTAL), SYMPTOMS, COPD ASSESSMENT TESTS, AND DEVICE BIOMETRICS (TEMPERATURE, PULSE, OXYGEN SATURATION, RESPIRATION RATE AND BREATH SOUNDS). IN PHASE II, THE PLATFORM WILL INCORPORATE SMART TRIGGERS THAT WILL ALERT PATIENTS IF CERTAIN ENVIRONMENTAL RISK FACTORS ARE MET, PROMPTING THEM TO ENGAGE WITH THE PLATFORM. THE SMART ALGORITHMS WILL THEN AUTOMATICALLY PREDICT THEIR COPD EXACERBATION RISK, ULTIMATELY TRIAGING THEM TO APPROPRIATE TREATMENT. PREDICTING AND PRE-EMPTING DISEASE EXACERBATION BY FACILITATING EARLY CONNECTIONS TO MEDICAL PROVIDERS FOR PROMPT AND EFFECTIVE TREATMENT WILL HAVE AN ENORMOUS IMPACT ON HEALTH OUTCOMES AND TREATMENT COSTS FOR RURAL COPD PATIENTS. ULTIMATELY, THIS PLATFORM WILL AUGMENT COPD SELF-MANAGEMENT, PROMOTE PREVENTIVE RESPIRATORY CARE, AND DISSEMINATE EVIDENCE-BASED COPD TREATMENTS, ALL DESIGNED TO REDUCE THE SIGNIFICANT HEALTH DISPARITIES IN A REMOTE, UNDERSERVED CENTRAL APPALACHIAN POPULATION WITH WORSE RESPIRATORY OUTCOMES.